Clinical trial
Vaccine Therapy in Treating Patients With Kidney Cancer
NCT00096629 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00096629 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Kidney Cancer |
| Official title | Injection of Renal Cell Carcinoma Patients With Human and Mouse Prostate Specific Membrane Antigen (PSMA) DNA: A Phase I Trial to Assess Safety and Immune Response |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine |
| Enrollment | 15 |
| Start date | Nov 1, 2003 |
| Primary completion | Apr 1, 2018 |
| Completion | Apr 1, 2018 |
| First posted | Nov 15, 2004 |
| Last update posted | Apr 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: